[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity

Rhea-AI Filing Summary

United Therapeutics Corporation (UTHR) reported insider activity by its CFO and Treasurer on a Form 4. On 11/24/2025, the executive exercised 21,000 stock options at an exercise price of $146.03 per share, converting them into common stock. That same day, multiple blocks of common shares were sold in market transactions, with weighted average sale prices reported in ranges generally around $466.72 to $482.42 per share. After these transactions, the reporting person directly held 8,142 shares of United Therapeutics common stock. The filing notes that the option exercise and subsequent sales were carried out under a Rule 10b5-1 trading plan entered into on August 5, 2025, which is a pre-arranged plan intended to allow insiders to trade shares over time according to preset instructions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EDGEMOND JAMES

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO AND TREASURER

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/24/2025		M(1)		21,000	A	$146.03	29,142	D
Common Stock	11/24/2025		S(1)		960	D	$467.3519(2)	28,182	D
Common Stock	11/24/2025		S(1)		1,850	D	$468.2863(3)	26,332	D
Common Stock	11/24/2025		S(1)		1,552	D	$469.3386(4)	24,780	D
Common Stock	11/24/2025		S(1)		2,919	D	$470.2208(5)	21,861	D
Common Stock	11/24/2025		S(1)		1,971	D	$471.8802(6)	19,890	D
Common Stock	11/24/2025		S(1)		1,788	D	$472.7256(7)	18,102	D
Common Stock	11/24/2025		S(1)		280	D	$473.5446(8)	17,822	D
Common Stock	11/24/2025		S(1)		1,560	D	$475.1074(9)	16,262	D
Common Stock	11/24/2025		S(1)		1,621	D	$476.0921(10)	14,641	D
Common Stock	11/24/2025		S(1)		2,989	D	$477.2173(11)	11,652	D
Common Stock	11/24/2025		S(1)		1,630	D	$478.1359(12)	10,022	D
Common Stock	11/24/2025		S(1)		315	D	$478.731(13)	9,707	D
Common Stock	11/24/2025		S(1)		640	D	$480.7103(14)	9,067	D
Common Stock	11/24/2025		S(1)		794	D	$481.5541(15)	8,273	D
Common Stock	11/24/2025		S(1)		131	D	$482.2947(16)	8,142	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$146.03	11/24/2025		M(1)			21,000	03/15/2020	03/15/2027	Common Stock	21,000	$0.00	517	D

Explanation of Responses:

1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025.

2. This transaction was executed in multiple trades at prices ranging from $466.72 to $467.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $467.72 to $468.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $468.76 to $469.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $469.77 to $470.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $471.33 to $472.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $472.34 to $473.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $473.40 to $474.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. This transaction was executed in multiple trades at prices ranging from $474.55 to $475.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

10. This transaction was executed in multiple trades at prices ranging from $475.60 to $476.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

11. This transaction was executed in multiple trades at prices ranging from $476.63 to $477.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

12. This transaction was executed in multiple trades at prices ranging from $477.63 to $478.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

13. This transaction was executed in multiple trades at prices ranging from $478.63 to $478.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

14. This transaction was executed in multiple trades at prices ranging from $480.10 to $481.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

15. This transaction was executed in multiple trades at prices ranging from $481.18 to $482.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

16. This transaction was executed in multiple trades at prices ranging from $482.21 to $482.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did United Therapeutics (UTHR) report on this Form 4?

The Form 4 reports that United Therapeutics' CFO and Treasurer exercised 21,000 stock options on 11/24/2025 at an exercise price of $146.03 per share and sold portions of the resulting common shares in multiple market transactions the same day.

What was the exercise price of the United Therapeutics (UTHR) stock options?

The reported stock option exercise price was $146.03 per share for 21,000 options, which were exercised on 11/24/2025 into United Therapeutics common stock.

At what prices were United Therapeutics (UTHR) shares sold by the executive?

The common stock sales on 11/24/2025 were executed in multiple trades, with weighted average prices reported at levels such as $467.3519, $468.2863, $470.2208, and up to about $482.2947. Each price reflects the weighted average of trades within disclosed ranges.

How many United Therapeutics (UTHR) shares does the reporting person hold after these transactions?

After the reported option exercise and share sales on 11/24/2025, the reporting person directly owned 8,142 shares of United Therapeutics common stock.

Was the United Therapeutics (UTHR) insider trading under a Rule 10b5-1 plan?

Yes. The filing states that the exercise of stock options and subsequent sale of shares were conducted pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025.

What role does the reporting person hold at United Therapeutics (UTHR)?

The reporting person is identified as an Officer of United Therapeutics, serving as CFO and Treasurer, and filed the Form 4 as an individual reporting person.

What derivative security was involved in this United Therapeutics (UTHR) Form 4?

The derivative security was a stock option on United Therapeutics common stock, with 21,000 underlying shares, an exercise price of $146.03, a date exercisable of 03/15/2020, and an expiration date of 03/15/2027. These options were exercised on 11/24/2025.